{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:44:16Z","timestamp":1791938656980,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40263-025-01235-y","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:48:55Z","timestamp":1760118535000},"page":"1341-1354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Atogepant on Sleep Quality and Sleep-Related Adverse Events in Adult Patients with Migraine: A Prospective Observational 12-Week Study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3598-0195","authenticated-orcid":false,"given":"Luigi Francesco","family":"Iannone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Boccalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Lo Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Brovia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Romozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Vernieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Gu\u00e9rzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"19","key":"1235_CR1","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383(19):1866\u201376.","journal-title":"N Engl J Med"},{"issue":"4","key":"1235_CR2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"RC Burch","year":"2019","unstructured":"Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin. 2019;37(4):631\u201349.","journal-title":"Neurol Clin"},{"issue":"1","key":"1235_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s10194-020-01192-5","volume":"21","author":"C Tiseo","year":"2020","unstructured":"Tiseo C, Vacca A, Felbush A, Filimonova T, Gai A, Glazyrina T, et al. Migraine and sleep disorders: a systematic review. J Headache Pain. 2020;21(1):126.","journal-title":"J Headache Pain"},{"issue":"10","key":"1235_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-013-0369-0","volume":"17","author":"ME Bigal","year":"2013","unstructured":"Bigal ME, Hargreaves RJ. Why does sleep stop migraine? Curr Pain Headache Rep. 2013;17(10):369.","journal-title":"Curr Pain Headache Rep"},{"issue":"7","key":"1235_CR5","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/head.13357","volume":"58","author":"JC Rains","year":"2018","unstructured":"Rains JC. Sleep and migraine: assessment and treatment of comorbid sleep disorders. Headache. 2018;58(7):1074\u201391.","journal-title":"Headache"},{"issue":"Suppl 2","key":"1235_CR6","doi-asserted-by":"publisher","first-page":"S138","DOI":"10.1007\/s10072-006-0589-8","volume":"27","author":"P Montagna","year":"2006","unstructured":"Montagna P. Hypothalamus, sleep and headaches. Neurol Sci. 2006;27(Suppl 2):S138\u201343.","journal-title":"Neurol Sci"},{"issue":"5","key":"1235_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.tins.2018.03.007","volume":"41","author":"RD Palmiter","year":"2018","unstructured":"Palmiter RD. The parabrachial nucleus: CGRP neurons function as a general alarm. Trends Neurosci. 2018;41(5):280\u201393.","journal-title":"Trends Neurosci"},{"issue":"22","key":"1235_CR8","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.cub.2014.09.077","volume":"24","author":"M Kunst","year":"2014","unstructured":"Kunst M, Hughes ME, Raccuglia D, Felix M, Li M, Barnett G, et al. Calcitonin gene-related peptide neurons mediate sleep-specific circadian output in Drosophila. Curr Biol. 2014;24(22):2652\u201364.","journal-title":"Curr Biol"},{"issue":"5","key":"1235_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.neuron.2017.10.009","volume":"96","author":"S Kaur","year":"2017","unstructured":"Kaur S, Wang JL, Ferrari L, Thankachan S, Kroeger D, Venner A, et al. A genetically defined circuit for arousal from sleep during hypercapnia. Neuron. 2017;96(5):1153-67.e5.","journal-title":"Neuron"},{"issue":"10483","key":"1235_CR10","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)00109-6","volume":"405","author":"J Versijpt","year":"2025","unstructured":"Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet. 2025;405(10483):1014\u201326.","journal-title":"Lancet"},{"issue":"4","key":"1235_CR11","doi-asserted-by":"publisher","first-page":"333102424130538","DOI":"10.1177\/03331024241305381","volume":"45","author":"R Ornello","year":"2025","unstructured":"Ornello R, Caponnetto V, Ahmed F, Al-Khazali HM, Ambrosini A, Ashina S, et al. Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia. 2025;45(4):3331024241305381.","journal-title":"Cephalalgia"},{"key":"1235_CR12","doi-asserted-by":"crossref","unstructured":"Viticchi G, Di Stefano V, Altamura C, Falsetti L, Torrente A, Brunelli N, et al. Effects of prophylactic drug therapies and anti-calcitonin peptide-related monoclonal antibodies on subjective sleep quality: an Italian multicenter study. Sleep Med. 2024;117:87-94.","DOI":"10.1016\/j.sleep.2024.03.026"},{"issue":"10","key":"1235_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103585","volume":"12","author":"L Pilati","year":"2023","unstructured":"Pilati L, Torrente A, Di Marco S, Ferlisi S, Notaro G, Romano M, et al. Erenumab and possible CGRP effect on chronotype in chronic migraine: a real-life study of 12 months treatment. J Clin Med. 2023;12(10):3585.","journal-title":"J Clin Med"},{"issue":"2","key":"1235_CR14","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103(2):1565\u2013644.","journal-title":"Physiol Rev"},{"key":"1235_CR15","doi-asserted-by":"crossref","unstructured":"Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P. Chapter 7\u2014CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention. In: Swanson JW, Matharu M (eds) Handbook of Clinical Neurology. Elsevier. 2024;107-24.","DOI":"10.1016\/B978-0-12-823357-3.00024-0"},{"issue":"10268","key":"1235_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"issue":"10404","key":"1235_CR17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10404):775\u201385.","journal-title":"The Lancet"},{"issue":"3","key":"1235_CR18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209\u201317.","journal-title":"Lancet Neurol"},{"key":"1235_CR19","doi-asserted-by":"crossref","unstructured":"Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, et al. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023;402(10419):2307-16.","DOI":"10.1016\/S0140-6736(23)01683-5"},{"issue":"9","key":"1235_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020;19(9):727\u201337.","journal-title":"Lancet Neurol"},{"key":"1235_CR21","first-page":"1","volume":"12","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Sun S, Wang Y. Adverse events associated with atogepant: a FAERS-based pharmacovigilance analysis. Expert Opin Drug Saf. 2024;12:1\u20137.","journal-title":"Expert Opin Drug Saf"},{"key":"1235_CR22","doi-asserted-by":"crossref","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention\u20142022 update. J Headache Pain. 2022;23(1):67.","DOI":"10.1186\/s10194-022-01431-x"},{"key":"1235_CR23","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.","DOI":"10.1177\/0333102417738202"},{"issue":"12","key":"1235_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jclinepi.2004.05.004","volume":"57","author":"M Martin","year":"2004","unstructured":"Martin M, Blaisdell B, Kwong JW, Bjorner JB. The short-form headache impact test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol. 2004;57(12):1271\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1235_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1046\/j.0333-1024.2001.00277.x","volume":"21","author":"D D'Amico","year":"2001","unstructured":"D\u2019Amico D, Mosconi P, Genco S, Usai S, Prudenzano AM, Grazzi L, et al. The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia. 2001;21(10):947\u201352.","journal-title":"Cephalalgia"},{"issue":"2","key":"1235_CR26","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/ana.21211","volume":"63","author":"RB Lipton","year":"2008","unstructured":"Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Ann Neurol. 2008;63(2):148\u201358.","journal-title":"Ann Neurol"},{"key":"1235_CR27","unstructured":"Buse D, Bigal M, Rupnow M, Reed M, Serrano D, Biondi D, et al. The migraine interictal burden scale (MIBS): results of a population-based validation study; 2007."},{"issue":"1","key":"1235_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","volume":"27","author":"H Hurst","year":"2004","unstructured":"Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26\u201335.","journal-title":"J Manipulative Physiol Ther"},{"issue":"2","key":"1235_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","volume":"28","author":"DJ Buysse","year":"1989","unstructured":"Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index (PSQI): a new instrument for psychiatric research and practice. Psychiatr Res. 1989;28(2):193\u2013221.","journal-title":"Psychiatr Res"},{"issue":"6","key":"1235_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0022-3999(00)00095-7","volume":"48","author":"CR Soldatos","year":"2000","unstructured":"Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens insomnia scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555\u201360.","journal-title":"J Psychosom Res"},{"issue":"3","key":"1235_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2466\/pms.107.3.691-706","volume":"107","author":"S Pallesen","year":"2008","unstructured":"Pallesen S, Bjorvatn B, Nordhus IH, Sivertsen B, Hjornevik M, Morin CM. A new scale for measuring insomnia: the Bergen insomnia scale. Percept Mot Skills. 2008;107(3):691\u2013706.","journal-title":"Percept Mot Skills"},{"issue":"4","key":"1235_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/sleep\/15.4.376","volume":"15","author":"MW Johns","year":"1992","unstructured":"Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15(4):376\u201381.","journal-title":"Sleep"},{"issue":"5","key":"1235_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/sleep\/34.5.601","volume":"34","author":"CM Morin","year":"2011","unstructured":"Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601\u20138.","journal-title":"Sleep"},{"issue":"6","key":"1235_CR34","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13543784.2019.1618830","volume":"28","author":"A Negro","year":"2019","unstructured":"Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555\u201367.","journal-title":"Expert Opin Investig Drugs"},{"key":"1235_CR35","doi-asserted-by":"crossref","unstructured":"Raja A, Asim R, Shuja MH, Raja S, Muhammad TS, Bajaj S, et al. Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults. Front Neurol. 2024;15.","DOI":"10.3389\/fneur.2024.1468961"},{"key":"1235_CR36","doi-asserted-by":"crossref","unstructured":"Pellitteri G, Pez S, Nilo A, Surcinelli A, Gigli GL, Lettieri C, et al. Erenumab impact on sleep assessed with questionnaires and home-polysomnography in patients with migraine: the ERESON study. Front Neurol. 2022;13.","DOI":"10.3389\/fneur.2022.869677"},{"issue":"1","key":"1235_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-022-01436-6","volume":"23","author":"M Silvestro","year":"2022","unstructured":"Silvestro M, Tessitore A, Orologio I, De Micco R, Tartaglione L, Trojsi F, et al. Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. J Headache Pain. 2022;23(1):69.","journal-title":"J Headache Pain."},{"issue":"13","key":"1235_CR38","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1177\/03331024221111526","volume":"42","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, De Cesaris F, Ferrari A, Benemei S, Fattori D, Chiarugi A. Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. Cephalalgia. 2022;42(13):1323\u201330.","journal-title":"Cephalalgia."},{"issue":"1","key":"1235_CR39","doi-asserted-by":"publisher","first-page":"333102423122618","DOI":"10.1177\/03331024231226186","volume":"44","author":"E Moore","year":"2024","unstructured":"Moore E, Bell IM, Fraley ME, Burgey CS, White RB, Li CC, et al. Pharmacologic characterization of atogepant: a potent and selective calcitonin gene-related peptide receptor antagonist. Cephalalgia. 2024;44(1):3331024231226186.","journal-title":"Cephalalgia"},{"issue":"1","key":"1235_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-021-01644-5","volume":"82","author":"ED Deeks","year":"2022","unstructured":"Deeks ED. Atogepant: first approval. Drugs. 2022;82(1):65\u201370.","journal-title":"Drugs"},{"issue":"2","key":"1235_CR41","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Munafo A, Burgalassi A, De Cesaris F, Vigani G, Altamura C, et al. Pharmacological differences and switching among anti-CGRP monoclonal antibodies: a narrative review. Headache. 2025;65(2):342\u201352.","journal-title":"Headache"},{"key":"1235_CR42","doi-asserted-by":"crossref","unstructured":"Labastida-Ram\u00edrez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, et al. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain. 2023;24(1):125.","DOI":"10.1186\/s10194-023-01644-8"},{"issue":"10","key":"1235_CR43","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1177\/0333102419844711","volume":"39","author":"KW Johnson","year":"2019","unstructured":"Johnson KW, Morin SM, Wroblewski VJ, Johnson MP. Peripheral and central nervous system distribution of the CGRP neutralizing antibody [(125)I] galcanezumab in male rats. Cephalalgia. 2019;39(10):1241\u20138.","journal-title":"Cephalalgia"},{"issue":"7","key":"1235_CR44","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/s41591-025-03679-7","volume":"31","author":"PJ Goadsby","year":"2025","unstructured":"Goadsby PJ, Ailani J, Dodick DW, Starling AJ, Liu C, Liu Y, et al. Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 prodrome trial. Nat Med. 2025;31(7):2179\u201385.","journal-title":"Nat Med"},{"key":"1235_CR45","doi-asserted-by":"publisher","first-page":"1529213","DOI":"10.3389\/fneur.2025.1529213","volume":"16","author":"NA Almansour","year":"2025","unstructured":"Almansour NA, Alsalamah SS, Alsubaie RS, Alshathri NN, Alhedyan YA, Althekair\u2019s FY. Association between migraine severity and sleep quality: a nationwide cross-sectional study. Front Neurol. 2025;16:1529213.","journal-title":"Front Neurol"},{"issue":"1","key":"1235_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/head.13435","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack Adams A, et al. Sleep disorders among people with migraine: results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59(1):32\u201345.","journal-title":"Headache"},{"issue":"2","key":"1235_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/head.14892","volume":"65","author":"B Blaszczyk","year":"2025","unstructured":"Blaszczyk B, Waliszewska-Prosol M, Smardz J, Wieckiewicz M, Wojakowska A, Martynowicz H. Exploring the associations of sleep bruxism and obstructive sleep apnea with migraine among patients with temporomandibular disorder: a polysomnographic study. Headache. 2025;65(2):242\u201357.","journal-title":"Headache"},{"issue":"1","key":"1235_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/j.pain.0000000000001053","volume":"159","author":"NS Simpson","year":"2018","unstructured":"Simpson NS, Scott-Sutherland J, Gautam S, Sethna N, Haack M. Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain. 2018;159(1):33\u201340.","journal-title":"Pain"},{"key":"1235_CR49","doi-asserted-by":"crossref","unstructured":"Silvestro M, Iannone LF, Orologio I, Tessitore A, Tedeschi G, Geppetti P, et al. Migraine treatment: towards new pharmacological targets. Int J Mol Sci. 2023;24(15).","DOI":"10.3390\/ijms241512268"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01235-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01235-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:08:08Z","timestamp":1762884488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01235-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01235-y","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"5 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The \u201c\n                      Societ\u00e0 Italiana per lo Studio delle Cefalee\n                      \u201d (SISC) is acknowledged for the \u201c\n                      Registro Italiano delle Cefalee\n                      (\n                      RICe\n                      ).\u201d All institutions and authors provided written permission to be included. All the questionnaires and data are used for non-commercial purposes and a free license agreement has been obtained if needed. Figure\n                      \n                      was created with Biorender.com.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgments"}},{"value":"Data supporting the findings in the present study are reported in the article and in the supplementary materials. The data collected and analyzed for the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"L.F.I. received financial support, consulting fees for the participation in advisory boards and support for attending meetings from: Teva, Eli Lilly, Lundbeck, Pfizer, and AbbVie; he is associate editor for\n                      Frontiers in Neurology Headache and Neurogenic Pain\n                      section. F.V. has received financial support from Allergan-AbbVie, Angelini, and Lundbeck for investigator-initiated trials; consulting fees for the participation in advisory boards from AbbVie, Angelini, Eli Lilly, Lundbeck, Organon, Novartis, Pfizer, and Teva; honoraria for scientific lectures and presentations from AbbVie, Eli Lilly, Lundbeck, Novartis, Organon, Pfizer, and Teva; support for attending meetings from Abbvie, Amgen, Eli Lilly, Lundbeck, Pfizer, and Teva; he has been principal investigator in clinical trials sponsored by AbbVie, Eli Lilly, Lundbeck, Pfizer, and Teva; he is co-specialty editor for\n                      Frontiers in Neurology Headache and Neurogenic Pain\n                      section. S.G. has received fees and honoraria for advisory boards, speaker panels, or clinical investigation studies from Novartis, Teva, Eli Lilly, Pfizer, Lundbeck, Angelini, and AbbVie. C.A. is associate editor for\n                      Frontiers of Human Neuroscience\n                      and\n                      Frontiers in Neurology Headache and Neurogenic Pain\n                      section; she received travel grants and\/or personal fees for advisory boards and speaker panels, from Novartis, Eli-Lilly, Lundbeck, Teva, Lusofarmaco, Laborest, Abbvie\/Allergan, Almirall, and Pfizer. Other authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The local Ethics committee approved the study as part of the Registro Italiano Cefalee (RICe) study (Studio RICe, 14591_oss CEAVC Studio RICe, 14591_oss and subsequent amendments).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients written an informed consent before the enrollment in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}